[Memantine and neurogenic bladder disorders within the bounds of spastic conditions].
The action of 1,3-dimethyl-5-aminoadamantane (DMAA, D-145, memantine, Memantine) on neurogenic bladder dysfunction in spastic conditions was investigated. Under memantine treatment micturition was considerably facilitated, and spontaneous, involuntary voiding reduced. Additionally, memantine effected a decrease of residual urine and toned down the vesicular sphincter by simultaneously enhancing detrusor activity. At the same time the patients reported a considerable diminution of spastic hypertonicity and improved mobility of the limb muscles.
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000031:analogs & derivatives*; D004576:Electromyography; D005260:Female; D006801:Humans; D008297:Male; D008559:Memantine / Q000627:therapeutic use*; D008875:Middle Aged; D009128:Muscle Spasticity / Q000150:complications*; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014554:Urination / Q000187:drug effects
D000547:Amantadine; D008559:Memantine
Memantin und neurogene Blasenstörungen im Rahmen spastischer Zustandsbilder.